395 related articles for article (PubMed ID: 19509500)
1. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
Klastersky J; Awada A; Aoun M; Paesmans M
Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
[TBL] [Abstract][Full Text] [Related]
2. The prevention of febrile neutropenia.
Pascoe J; Cullen M
Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
[TBL] [Abstract][Full Text] [Related]
3. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
Timmer-Bonte JN; Tjan-Heijnen VC
Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
[TBL] [Abstract][Full Text] [Related]
4. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
Adams JR; Angelotta C; Bennett CL
J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
[No Abstract] [Full Text] [Related]
5. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
7. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
9. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
10. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?
Klastersky J; Awada A
Crit Rev Oncol Hematol; 2011 Apr; 78(1):17-23. PubMed ID: 20227290
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors for febrile neutropenia].
Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
[TBL] [Abstract][Full Text] [Related]
12. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
Morstyn G; Foote M; Perkins D; Vincent M
Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
[TBL] [Abstract][Full Text] [Related]
13. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
Wingard JR; Elmongy M
Crit Rev Oncol Hematol; 2009 Nov; 72(2):144-54. PubMed ID: 19237297
[TBL] [Abstract][Full Text] [Related]
14. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
15. [Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia].
Murakawa Y
Gan To Kagaku Ryoho; 2013 Jun; 40(6):693-6. PubMed ID: 23863645
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
17. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
18. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
[TBL] [Abstract][Full Text] [Related]
19. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].
Carrato A; Guillén-Ponce C; Grande-Pulido E
Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
Rader M
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
